telehealth.helpFind my match

Home WikiTelehealth Pharmacy & compounding

Compounding pharmacy

From WikiTelehealth, the telehealth.help reference · Last updated

A compounding pharmacy is a pharmacy that prepares a medicine by combining, mixing or changing ingredients to fit the needs of an individual patient. Compounded medicines are not FDA-approved products, and in the United States they are made under sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act.

Compounding pharmacy
TypePharmacy that prepares patient-specific medicines
Federal lawFD&C Act sections 503A and 503B
Main regulatorState boards of pharmacy (503A); FDA (503B)
FDA approval of productsNo
Key lawDrug Quality and Security Act (November 27, 2013)

Definition

Compounding is the practice of preparing a drug that is not made by a drug manufacturer as a finished product. A compounding pharmacy may make a liquid version of a pill for a child, leave out a dye that causes an allergy, or prepare a strength that is not sold commercially.

A compounded medicine is not reviewed by the FDA for safety, effectiveness or quality before it is sold. It is made for a patient under a prescription, or for a clinic under the rules for outsourcing facilities.

Federal law sets 2 main paths for compounding. Traditional compounding pharmacies work under section 503A and are licensed and inspected mainly by state boards of pharmacy (see 503A pharmacy). Outsourcing facilities work under section 503B, register with the FDA and follow current good manufacturing practice, or CGMP (see 503B outsourcing facility).

Congress passed the Drug Quality and Security Act on November 27, 2013, after a 2012 fungal meningitis outbreak linked to a compounding pharmacy. That law created the 503B category and kept the rest of section 503A in place.

Compounding and GLP-1 medicines

Compounding pharmacies became a major source of GLP-1 medicines in 2022 to 2025, when semaglutide and tirzepatide injections were on the FDA drug shortage list. During a shortage, federal law allows compounders to make copies of a drug in short supply.

The FDA declared the tirzepatide shortage resolved on December 19, 2024, and the semaglutide shortage resolved on February 21, 2025. Compounding of these drugs continues under the normal 503A rules, which require a prescription for an individual patient and limit products that are essentially copies of an approved drug. See compounded semaglutide and compounded tirzepatide.

Compounded versus brand-name drugs

A brand-name drug goes through FDA review of clinical trials, manufacturing and labeling. A compounded drug made by a compounding pharmacy uses the same active ingredient in many cases, but the finished product is not FDA-approved and may differ in strength, form or added ingredients. A side-by-side comparison is on the compounded vs brand page.

Compare compounded and brand programs

See also

References

  1. FDA: Human drug compounding. fda.gov
  2. FDA: Human drug compounding laws. fda.gov
  3. FDA: FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize (updated April 1, 2026). fda.gov
  4. FDA: Resolution of tirzepatide injection product shortage (December 19, 2024). fda.gov
  5. FDA: Resolution of shortages of semaglutide injection products (February 21, 2025). fda.gov

Last updated . Category: Pharmacy & compounding. Browse all 38 WikiTelehealth entries.